See more : PT Dua Putra Utama Makmur Tbk (DPUM.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Maja Agung Latexindo Tbk. (SURI.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Maja Agung Latexindo Tbk., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- AMP Limited (AMLTF) Income Statement Analysis – Financial Results
- DMG Blockchain Solutions Inc. (6AX.F) Income Statement Analysis – Financial Results
- TScan Therapeutics, Inc. (TCRX) Income Statement Analysis – Financial Results
- Nymox Pharmaceutical Corporation (NYMXF) Income Statement Analysis – Financial Results
- Banco BBVA Argentina S.A. (XBBAR.MC) Income Statement Analysis – Financial Results
Maja Agung Latexindo Tbk. (SURI.JK)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
About Maja Agung Latexindo Tbk.
PT Maja Agung Latexindo Tbk is engaged in the filed of manufacturing, especially producing medical gloves. The business activities of the company is to engage in rubber goods industry to support health needs, including contraceptive covers, pacifiers, compression devices, medical gloves and urinary catheters.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 81.72B | 93.33B | 338.13B | 313.37B |
| Cost of Revenue | 66.78B | 77.97B | 282.50B | 261.10B |
| Gross Profit | 14.93B | 15.36B | 55.63B | 52.28B |
| Gross Profit Ratio | 18.28% | 16.46% | 16.45% | 16.68% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.23B | 1.34B | 1.85B | 1.12B |
| Selling & Marketing | 1.32B | 1.93B | 11.10B | 8.87B |
| SG&A | 4.55B | 3.27B | 12.94B | 9.99B |
| Other Expenses | 9.64B | 584.45M | 3.90B | 1.40B |
| Operating Expenses | 14.19B | 20.52B | 21.13B | 18.56B |
| Cost & Expenses | 80.97B | 98.48B | 303.62B | 279.66B |
| Interest Income | 13.63M | 1.29M | 207.20M | 162.64M |
| Interest Expense | 56.18M | 76.63M | 222.27M | 116.92M |
| Depreciation & Amortization | 7.31M | 50.16M | 77.30M | 79.98M |
| EBITDA | 978.07M | -5.11B | 34.58B | 33.79B |
| EBITDA Ratio | 1.20% | -23.44% | 10.23% | 10.78% |
| Operating Income | 744.64M | 1.20B | 32.24B | 33.71B |
| Operating Income Ratio | 0.91% | 1.28% | 9.53% | 10.76% |
| Total Other Income/Expenses | 6.64B | 12.01B | 1.79B | 3.26B |
| Income Before Tax | 7.39B | 13.21B | 34.03B | 36.98B |
| Income Before Tax Ratio | 9.04% | 14.16% | 10.06% | 11.80% |
| Income Tax Expense | 1.92B | 2.99B | 7.60B | 8.15B |
| Net Income | 5.47B | 10.23B | 26.43B | 28.82B |
| Net Income Ratio | 6.69% | 10.96% | 7.82% | 9.20% |
| EPS | 1.17 | 1.61 | 4.17 | 4.55 |
| EPS Diluted | 1.17 | 1.61 | 4.17 | 4.55 |
| Weighted Avg Shares Out | 4.66B | 6.33B | 6.33B | 6.33B |
| Weighted Avg Shares Out (Dil) | 4.66B | 6.33B | 6.33B | 6.33B |
Source: https://incomestatements.info
Category: Stock Reports